Hilbe W, Dirnhofer S, Oberwasserlechner F, Eisterer W, Ammann K, Schmid T, Hilbe G, Thaler J, Wöll E
Department of Internal Medicine, Innsbruck University Hospital, Anichstrasse 35, A-6020 Innsbruck, Austria.
J Clin Pathol. 2003 Oct;56(10):736-41. doi: 10.1136/jcp.56.10.736.
To investigate the immunohistochemical expression of a panel of biologically relevant markers in patients with non-small cell lung cancer using fresh frozen specimens and to test their prognostic relevance for identification of patients at risk.
Seventy nine tumour infiltrated lung cancer specimens and 66 adjacent histologically tumour free tissues were analysed; 11 postmortem specimens from patients who did not suffer from a malignant disease served as a control group. Cryostat sections were stained with monoclonal antibodies against epidermal growth factor receptor (EGFR), c-erbB-2, c-erbB-3, CD82, Ki-67, p120, p53, bcl-2, and CD31.
At least one of the tested markers was raised above the defined cut off point in 75 of the tumours. In 55, three to six factors were increased. EGFR was raised in 32, c-erbB-2 in 29, c-erbB-3 in 46, p53 in 29, bcl-2 in 26, Ki-67 in 36, p120 in 46, and CD31 in 29. None of the tested parameters was significant in univariate survival analysis. In a second step, three variables were combined (c-erbB3, p53, and microvessel density), and cases with increased expression of two or three parameters proved to have a significantly lower survival probability than those expressing none or only one factor. In the tumour free group only 10 showed raised marker expression.
Characterisation of tumour cells in surgical specimens with immunohistological markers could help identify those patients at risk for early cancer death who could possibly profit from adjuvant treatment after curative tumour resection.
使用新鲜冷冻标本研究一组生物学相关标志物在非小细胞肺癌患者中的免疫组化表达,并测试其对识别高危患者的预后相关性。
分析了79例肿瘤浸润的肺癌标本和66例组织学上无肿瘤的相邻组织;11例未患恶性疾病患者的尸检标本作为对照组。冰冻切片用抗表皮生长因子受体(EGFR)、c-erbB-2、c-erbB-3、CD82、Ki-67、p120、p53、bcl-2和CD31的单克隆抗体染色。
在75个肿瘤中,至少有一个测试标志物高于定义的截断点。在55个肿瘤中,三到六个因素增加。EGFR升高的有32个,c-erbB-2升高的有29个,c-erbB-3升高的有46个,p53升高的有29个,bcl-2升高的有26个,Ki-67升高的有36个,p120升高的有46个,CD31升高的有29个。在单因素生存分析中,没有一个测试参数具有显著性。第二步,将三个变量组合(c-erbB3、p53和微血管密度),发现两个或三个参数表达增加的病例的生存概率明显低于那些无表达或仅一个因素表达增加的病例。在无肿瘤组中,只有10个显示标志物表达升高。
用免疫组织学标志物对手术标本中的肿瘤细胞进行特征化,有助于识别那些有早期癌症死亡风险的患者,这些患者可能从根治性肿瘤切除后的辅助治疗中获益。